

Venetoclax in combination with hypomethylating agents in newly diagnosed and relapsed *CBFβ::MYH11*⁺ acute myeloid leukemia

Authors

Ziyu Feng,^{1*} Xiaohui Hu,^{1*} Weiyang Li,¹ Ting Xu,¹ Yang Xu,^{1,2} Shengli Xue,^{1,2} Huiying Qiu,^{1,2} Xiaowen Tang,^{1,2} Yue Han,^{1,2,3} Suning Chen,^{1,2} Aining Sun,^{1,2} Yanming Zhang,⁴ Depei Wu^{1,2,3,5} and Ying Wang^{1,2}

¹National Clinical Research Center for Hematologic Diseases, Department of Hematology, The First Affiliated Hospital of Soochow University, Suzhou; ²Institute of Blood and Marrow Transplantation, Collaborative Innovation Center of Hematology, Soochow University, Suzhou; ³Key Laboratory of Thrombosis and Hemostasis of Ministry of Health, Suzhou; ⁴Department of Hematology, The Second People's Hospital of Huai'an, Huai'an and ⁵State Key Laboratory of Radiation Medicine and Protection, Soochow University, Suzhou, China

**ZYF and XHH contributed equally as first authors.*

Correspondence:

Y. ZHANG - zhangyanming2005@126.com

D. WU - wudepei@suda.edu.cn

Y. WANG - wangying77@suda.edu.cn

<https://doi.org/10.3324/haematol.2024.286836>

Received: October 24, 2024.

Accepted: February 13, 2025.

Early view: February 20, 2025.

©2025 Ferrata Storti Foundation


Published under a CC BY-NC license



Supplementary Table 1. Next-generation sequencing (NGS) panel

ABL1	CALR	CSF1R	FAT1	KLF2	PAX5	SAMHD1	TCF3
ANKRD26	CARD11	CSF3R	FBXW7	KMT2A	PDCD1LG2	SETBP1	TET1
APC	CBL	CSMD1	FLT3	KMT2C	PDGFRA	SETD2	TET2
ARID1A	CCND1	CTCF	FOXO1	KMT2D	PDGFRB	SF3B1	TNFAIP3
ARID1B	CCND2	CXCR4	GATA1	KRAS	PHF6	SH2B3	TNFRSF1
ARID2	CCND3	DDX3X	GATA2	MAP2K1	PIGA	SMC1A	TP53
ARID5B	CD274	DDX41	GARA3	MAPK1	PIK3CA	SMC2	TP63
ASXL1	CD28	DHX15	GNA13	MECOM	PIM1	SMC3	TP73
ASXL2	CD58	DIS3	HRAS	MED12	PLCG1	SOS1	TRAF3
ATM	CD79A	DNM2	ID3	MEF2B	PLCG2	SPEN	TYK2
B2M	CD79B	DNMT3A	IDH1	MPL	PPM1D	SRP72	U2AF1
BCL2	CDKN1A	ECT2L	IDH2	MUM1	PRDM1	SRSF2	UNC13D
BCL6	CDKN2A	EED	IGLL5	MYC	PTEN	STAG2	WT1
BCOR	CDKN2B	EGFR	IKZF1	MYD88	PTPN11	STAT1	XPO1
BCORL1	CDKN2C	EGR2	IKZF3	NF1	PTPRD	STAT2	ZAP70
BIRC3	CEBPA	EP300	IL7R	NFKB1	RAD21	STAT3	ZBTB7A
BRAF	CEBPE	EPOR	IRF4	NFKB2	RAF1	STAT4	ZMYM3
BRCA1	CHD8	ERBB3	JAK1	NFKBIE	RB1	STAT5A	ZRSR2
BRCA2	CIITA	ETNK1	JAK2	NOTCH1	RELN	STAT5B	
BRCC3	CRBN	ETV6	JAK3	NOTCH2	RHOA	STAT6	
BTG1	CREBBP	EZH2	KDM6A	NPM1	RPS15	SUZ12	
BTK	CRLF2	FAM46C	KIT	NRAS	RUNX1	TBL1XR1	

Supplementary Figure 1. RFS according to molecular MRD after first cycle of Ven + HMA.



Supplementary Figure 2. Clonal evolution in 4 relapsed patients.

